Skip to main content
Clinical Trials/NCT03750890
NCT03750890
Unknown
Not Applicable

A New Strategy for the Visulation of Molecular Genotype in Glioma Evolution Based on the Radiomics and Microomics

Tongji Hospital1 site in 1 country1,000 target enrollmentJanuary 1, 2019
ConditionsGlioma of Brain

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Glioma of Brain
Sponsor
Tongji Hospital
Enrollment
1000
Locations
1
Primary Endpoint
microomics molecular markers (IDH mutation, 1p/19q status, P53 mutation, TERT and ATRX mutation, EGFR amplification and mutation, MGMT methylation status, PTEN mutation, ZM fusion gene and other gene features)
Last Updated
7 years ago

Overview

Brief Summary

The key molecular changes in the progression of glioma are closely related to tumor heterogeneity, pathological grade, precision treatment and prognosis of glioma. At present, a visually quantitative assessment criteria about the key molecular typing of glioma is still absent. Based on the previous research, this project intends to establish a multi-dimensional database of glioma from clinical, radiomics and microomics levels. The investigators aim to filter out the specific molecular markers in the progression of glioma and explore the intrinsic connection of radiomics features and microomics molecular markers by using bioinformatics integration analysis and artificial intelligence multiple kernel learning. Thus, the investigators could determine the specific molecular mechanism in the progression of glioma, and establish a visually quantitative assessment system of pre-operative precisive grading, molecular typing discrimination and prognosis prediction. The completion of this project is of great significance for improving molecular diagnostic level of glioma, guiding individualized diagnosis and treatment decisions, and improving the survival rate of patients.

Registry
clinicaltrials.gov
Start Date
January 1, 2019
End Date
December 31, 2022
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • postoperative pathological and genetic test confirmed brain glioma;
  • The preoperative Clear and complete multimodal imaging data were collected within 10 days.

Exclusion Criteria

  • patients who underwent surgery more than 4 weeks after MRI;
  • patients with motion artifacts.

Outcomes

Primary Outcomes

microomics molecular markers (IDH mutation, 1p/19q status, P53 mutation, TERT and ATRX mutation, EGFR amplification and mutation, MGMT methylation status, PTEN mutation, ZM fusion gene and other gene features)

Time Frame: through study completion, an average of 3 years

the key molecular markers (IDH mutation, 1p/19q status, P53 mutation, TERT and ATRX mutation, EGFR amplification and mutation, MGMT methylation status, PTEN mutation, ZM fusion gene and other gene features) in the progression of glioma

radiomics features(the parameters of T1WI, T2WI, DWI, DKI, ASL, ESWAN, DCE, MRS and so on)

Time Frame: through study completion, an average of 3 years

the radiomics features(the parameters of T1WI, T2WI, DWI, DKI, ASL, ESWAN, DCE, MRS and so on)in the progression of glioma

Study Sites (1)

Loading locations...

Similar Trials